Oncolytics Biotech Inc. (NASDAQ:ONCY) Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC boosted its position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) by 33.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 269,699 shares of the company’s stock after acquiring an additional 68,246 shares during the period. International Assets Investment Management LLC owned about 0.36% of Oncolytics Biotech worth $364,000 as of its most recent SEC filing.

Separately, Advisor Resource Council acquired a new position in shares of Oncolytics Biotech in the 4th quarter valued at $135,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

Wall Street Analyst Weigh In

ONCY has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Oncolytics Biotech in a report on Friday, January 12th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Oncolytics Biotech in a research note on Wednesday, February 14th. Finally, Raymond James assumed coverage on shares of Oncolytics Biotech in a research note on Thursday, April 4th. They set an “outperform” rating and a $3.00 price target for the company.

Oncolytics Biotech Price Performance

Shares of NASDAQ:ONCY opened at $1.09 on Friday. The stock has a market cap of $82.21 million, a P/E ratio of -3.63 and a beta of 1.93. The firm has a fifty day moving average price of $1.06 and a 200 day moving average price of $1.28. Oncolytics Biotech Inc. has a 1-year low of $0.88 and a 1-year high of $3.39.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. Sell-side analysts expect that Oncolytics Biotech Inc. will post -0.32 EPS for the current fiscal year.

Oncolytics Biotech Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.